@article {530,
	title = {The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone},
	journal = {Blood},
	volume = {106},
	year = {2005},
	note = {Flomenberg, Neal Devine, Steven M Dipersio, John F Liesveld, Jane L McCarty, John M Rowley, Scott D Vesole, David H Badel, Karin Calandra, Gary Blood. 2005 Sep 1;106(5):1867-74. Epub 2005 May 12.},
	month = {Sep 1},
	pages = {1867 - 74},
	type = {Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov{\textquoteright}t},
	edition = {38486},
	abstract = {Hematopoietic progenitor cells (HPCs) traffic to and are retained in the marrow through the trophic effects of the chemokine stromal cell-derived factor-1alpha (SDF-1alpha) binding to its receptor, CXC chemokine receptor 4 (CXCR4). AMD3100 reversibly inhibits SDF-1alpha/CXCR4 binding, and AMD3100 administration mobilizes CD34(+) cells into the circulation. We therefore tested the hypotheses that the combination of AMD3100 plus granulocyte colony-stimulating factor (G-CSF) (hereafter A + G) would be superior to G-CSF alone (hereafter G) in mobilizing hematopoietic progenitor cells (HPCs) and that A + G-mobilized cells would engraft as well as G-mobilized cells. The primary objective was to determine whether patients mobilized more progenitor cells per unit of blood volume of apheresis after A + G administration versus G alone. Secondary objectives were to determine whether patients mobilized with A + G compared with G alone required fewer apheresis procedures to reach the target level at least 5 x 10(6) CD34(+) cells/kg for transplantation and to determine whether patients mobilized with A + G had at least a 90\% success rate of autologous transplantation as assessed by neutrophil engraftment by day 21. Each patient served as his or her own control in a sequential mobilization design. All study objectives were met without significant toxicity. The results demonstrate that the combination of A + G is generally safe, effective, and superior to G alone for autologous HPC mobilization.},
	keywords = {Adolescent, Adult, Aged, Antigens, CD34 / analysis, Antineoplastic Combined Chemotherapy Protocols / *administration \&, dosage / adverse effects / pharmacology, Drug Synergism, effects / pharmacology, Female, Granulocyte Colony-Stimulating Factor / *administration \& dosage / adverse, Hematopoietic Stem Cell Mobilization / *methods, Heterocyclic Compounds / *administration \& dosage / adverse, Humans, Male, Middle Aged},
	issn = {0006-4971 (Print) 0006-4971 (Linking)},
	doi = {10.1182/blood-2005-02-0468},
	author = {Flomenberg,N. and Devine,S. M. and Dipersio,J. F. and Liesveld,J. L. and McCarty,J. M. and Rowley,S. D. and Vesole,D. H. and Badel,K. and Calandra,G.}
}
